References
- Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of COPD [updated 2018] Available from: http://www.goldcopd.orgAccessed February 12, 2018
- BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
- CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 μg therapy in COPD: a randomized, controlled studyChest2014145598199124385182
- MartinezFJRabeKFFergusonGTEfficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPDChest2017151234035727916620
- D’UrzoADRennardSIKerwinEMEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
- SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
- YuAPGuérinAPonce de LeonDClinical and economic outcomes of multiple versus single long-acting inhalers in COPDRespir Med2011105121861187121807487
- YuAPGuérinAPonce de LeonDTherapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalersJ Med Econ201114448649621679019
- Bevespi Aerosphere™ (glycopyrrolate and formoterol fumarate) inhalational aerosol, for oral inhalation use [prescribing information]WilmingtonAstraZeneca Pharmaceuticals LP2017 Available from: http://www.azpicentral.com/bevespi/bevespi_pi.pdfAccessed February 12, 2018
- Lechuga-BallesterosDNogaBVehringRCummingsRHDwivediSKNovel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthmaFuture Med Chem20113131703171821942257
- VehringRLechuga-BallesterosDJoshiVNogaBDwivediSKCosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalersLangmuir20122842150151502322985189
- DotyASchroederJVangKDrug delivery from an innovative LAMA/LABA co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and reliabilityAAPS Pharm Sci Tech2018192837844
- HananiaNATashkinDPKerwinEMLong-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary diseaseRespir Med201712610511528427541
- ReisnerCFabbriLMKerwinEMA randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseRespir Res2017181828061907
- LiLLiXXuLShengYHuangJZhengQSystematic evaluation of dose accumulation studies in clinical pharmacokineticsCurr Drug Metab201314560561523701162
- EklundATrondeAJohannes-HellbergIGillenMBorgströmLPharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adultsBiopharm Drug Dispos200829738239518623040
- LuDLeeSLLionbergerRAInternational guidelines for bioequivalence of locally acting orally inhaled drug products: similarities and differencesAAPS J201517354655725758352
- BattistiWPWagerEBaltzerLGood publication practice for communicating company-sponsored medical research: GPP3Ann Intern Med2015163646146426259067